4SC-207
4SC-207 is a potent, orally active microtubule inhibitor. 4SC-207 inhibits microtubule growth to inhibit tumor cell proliferation in vitro and in vivo, and promotes a mitotic delay/arrest, followed by apoptosis or aberrant divisions. 4SC-207 inhibits tumor growth in taxane resistant xenograft mouse models. 4SC-207 can be used for cancer research, such as colon adenocarcinoma and other malignancies.
For research use only. We do not sell to patients.
- CAS No.: 871015-11-1
- Formula: C19H18N4O3S
- Molecular Weight:382.44
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
4SC-207 (10 nM-100 μM, 24-72 h) reduces cell viability and induces a G2/M arrest only in proliferating RKO cells[1].
4SC-207 (10 nM-100 nM, 9 h) induces, in a dose dependent manner, aberrant divisions, following a prolonged mitosis, or mitotic arrest in HeLa wt cells, and affects all cells at 100 nM[1].
4SC-207 (0-2 μM, 0-20 min) inhibits tubulin polymerization in a dose-dependent manner in an in vitro assay using purified pig-brain tubulin[1].
4SC-207 (50-100 nM) reduces microtubule growth speeds in living HeLa cells[1].
4SC-207 (72 h) exhibits potent anti-proliferative agent active on a broad range of tumor cells with an average GI50 of 11nM, and is active in multi-drug resistant cell lines, such as HCT-15 and ACHN[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:RKO cells
-
Concentration:10 nM-100 μM
-
Incubation Time:72 h
-
Result:Reduced the percentage of viable cells from 100% to 20% when added at or above a concentration of 100 nM.
-
Cell Line:RKO cells
-
Concentration:100 nM
-
Incubation Time:24 h
-
Result:Showed a strong increase in the percentage of cells in G2/M phase (52% compared to 24% of DMSO-treated cells).
Decreased the amount of cells in G1 and S phases (respectively 14% and 10% compared to 53% and 20% in control cells).
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female SCID mice subcutaneously implanted with HCT-15 colon cancer cells[1]
-
Dosage:60 and 120 mg/kg
-
Administration:i.g., 3 times weekly for 3 weeks
-
Result:Resulted in a reduction in tumor growth, in a dose dependent manner, without evidence of toxicity based on body weight measurements.
Resulted in significant tumor reduction at day 12, day 14, and day 19 at 120 mg/kg.
Chemical Information
-
CAS No. 871015-11-1
-
Molecular Weight 382.44
-
Formula C19H18N4O3S
-
SMILES
O=C(N1CCC(C(C#N)=C(NC(/C=C/C2=CC=CN=C2)=O)S3)=C3C1)OCC
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
4SC-207 Related Classifications
HY-111251 Related Classifications
Powered by Bioz